甲状腺癌分子影像诊断与靶向治疗研究进展

常伟; 高再荣; 常伟; 高再荣

doi:10.3760/cma.j.issn.1673-4114.2009.04.008

[1]

Weissleder R.Molecular imaging:exploring the next frontier.Radiology,1999,212(3):609-614.

[2]

Bartolazzi A,Oiiandi F,Sagiorato E,et al.Galectin-3-expression analysis in the surigical selection follicular thyroid nodules with indeterminate fine-needle aspiration cytology:a prospective multicentre study.Lauicet Oncol,2008,9(6):543-549.

[3]

Bartolazzi A,D'Alessandria C,Pari sella MG,et al.Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.PLoS One,2008,3(11):e3768.

[4]

Haslinghuis LM,Krenning EP,De Herder WW,et al.Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.J Endocrinol Invest,2001,24(6):415-422.

[5]

Giammarile F,Houzard C,Bournaud C,et al. Diagnostic management of suspected metastatic thyroid carcinoma:clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.Eur J Endocrinol,2004,150(3):277-283.

[6]

Kwekkeboom DJ,Teunissen JJ,Bakker W H,et al.Radiolabeled somatostatin analog[¹⁷⁷Lu-DOTA⁰,Tyr³] octreotate in patients with endocrine gastroenteropancreatic tumors.J Clin Oncol,2005,23(12):2754-2762,.

[7]

张浩然,马庆杰.赵劼,等.¹³¹I-chTNT在分化型甲状腺癌肺转移患者体内的生物学分布.中国老年学杂志,2009,29(1):65-67.

[8]

Helal BO,Merlet P,Toubert ME,et al.Clinical impact of ¹⁸F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative ¹³¹I scanning results after therapy.J Nucl Med,2001,42(10):1464-1469.

[9]

Petrich T,B rner AR Otto D,et al.Influence of rhTSH on[¹⁸F] fluorodeoxyglucose uptake by differentiated thyroid carcinoma.Eur J Nucl Med Mol Imaging,2002,29(5):641-647.

[10]

Phan HT,Jager PL,Paans AM,et al.The diagnostic value of ¹²⁴I-PET in patients with differentiated thyroid cancer.Eur J Nucl Med Mol Imaging,2008,35(5):958-965.

[11]

Hsieh HJ,Lin SH,Lin KH,et al.The feasibility of ¹¹C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with ¹⁸F-FDG-PET.Ann Nucl Med,2008,22(6):533-538.

[12]

Arslan N,llgan S,Yuksel D,et al.Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.Clin Nucl Med,2001,26(8):683-688.

[13]

Gao Z,Biersack HJ,Ezziddirt S,et al.The role of combined imaging in metastatic medullary thyroid carcinoma:¹¹¹In-DTPA-octreotide and ^l31I/^l23I-MIBG as predictors for radionuclide therapy.J Cancer Res Clin Oncol,2004,130(11):649-656.

[14]

de Groot JW,Links TP,Jager PL,et al.Impact of ^l8F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence recurrent or residual medullary thyroid cancer.Ann Surg Oncol,2004,11(8):786-794.

[15]

Hoegerle S,Altehoefer C,Ghanem N,et al.^l8F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.Eur J Nucl Med,2001,28(1):64-71.

[16]

Cengic N,Baker CH,Schütz M,et al.A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.J Clin Endocrinol Metab,2005,90(8):4457-4464.

[17]

Lee YJ,Chung JK,Shin JH,et al.In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene.Thyroid,2004,14(11):889-895.